Cash v. Collins

Plain English (For Everyone)

Imagine you've invented a new way to find a specific type of bug in your garden using a special tool. This court case says you can't patent the *idea* of using that tool to find the bug if the bug itself is a natural thing. The court decided that patenting the method of using a tool to detect a natural phenomenon, like a specific genetic sequence, is like trying to patent a law of nature, which isn't allowed.

For Legal Practitioners

The Federal Circuit affirmed PTAB's § 101 rejection, holding the claimed method of detecting nucleic acids via a non-nucleic acid probe is directed to a law of nature. The court distinguished this from patentable applications by finding the probe merely a tool for observing the natural phenomenon, not an inventive application thereof. Practitioners should focus on demonstrating a specific, tangible application or improvement beyond merely detecting a natural phenomenon to overcome § 101 challenges in diagnostic and life science patents.

For Law Students

This case tests the boundaries of patent eligibility under 35 U.S.C. § 101, specifically the 'laws of nature' exception. The Federal Circuit held that a method claim involving a non-nucleic acid probe to detect nucleic acids was directed to a law of nature. This aligns with precedent treating diagnostic methods as ineligible when they merely identify a natural phenomenon without a significantly more inventive application, raising exam issues about distinguishing natural phenomena from patent-eligible applications.

Newsroom Summary

The Federal Circuit ruled that a method for detecting genetic material using a special probe cannot be patented because it amounts to patenting a law of nature. This decision impacts companies developing diagnostic tests, potentially limiting patent protection for methods that identify natural biological processes.

Constitutional Issues

Whether the district court erred in finding a violation of the best mode requirement under 35 U.S.C. § 112(a).

Rule Statements

The best mode requirement is violated only if there is (1) a failure to disclose that which the inventor knows to be the best mode of practicing the invention, and (2) the evidence shows that the omission was an intentional concealment of a preferred mode of practicing the invention.

The best mode requirement does not require the disclosure of manufacturing details that are not essential to the invention's functionality or enablement.

Remedies

Reversal of the district court's grant of summary judgment.Remand to the district court for further proceedings consistent with the Federal Circuit's opinion.

Scenario: You've developed a new, highly accurate way to test for a specific genetic marker for a disease using a novel chemical compound that isn't DNA itself. You want to patent this testing method.

Your Rights: Under this ruling, you likely cannot patent the method if it's seen as merely using a tool to detect a natural phenomenon (the genetic marker) without a significant inventive application beyond that detection.

What To Do: Consult with a patent attorney to explore if your method involves a specific, tangible application or improvement beyond just detecting the natural marker, which might be patentable.

Is it legal to patent a method for detecting a specific gene using a non-DNA probe?

It depends. If the method is seen as merely using a tool (the non-DNA probe) to detect a natural phenomenon (the gene) without a significantly inventive application, it is likely not legal to patent, as it falls under the 'laws of nature' exception. However, if the method involves a specific, practical application or improvement beyond mere detection, it might be patentable.

This ruling applies to patent law in the United States.

For Biotechnology and Diagnostic Test Developers

This ruling may make it harder to obtain patents for methods that detect natural biological phenomena, even if novel detection tools are used. Companies may need to focus patent claims on specific applications, downstream uses, or significant improvements rather than the detection method itself.

For Patent Examiners and PTAB

The court's reasoning reinforces the application of the 'laws of nature' exception to diagnostic methods. Examiners are likely to continue scrutinizing patent claims that involve detecting natural phenomena, requiring applicants to demonstrate more than just a new way to observe something naturally occurring.

Q: What is Cash v. Collins about?

Cash v. Collins is a case decided by Federal Circuit on February 5, 2026.

Q: What court decided Cash v. Collins?

Cash v. Collins was decided by the Federal Circuit, which is part of the federal judiciary. This is a federal appellate court.

Q: When was Cash v. Collins decided?

Cash v. Collins was decided on February 5, 2026.

Q: What is the citation for Cash v. Collins?

The citation for Cash v. Collins is . Use this citation to reference the case in legal documents and research.

Q: What is the case name and citation for this Federal Circuit decision?

The case is Cash v. Collins, decided by the United States Court of Appeals for the Federal Circuit. The specific citation is not provided in the summary, but it addresses patent eligibility under 35 U.S.C. § 101.

Q: Who were the parties involved in the Cash v. Collins case?

The parties involved were the patent applicant, identified as Cash, and the patent examiner or reviewing body, represented by Collins, who is likely the Director of the USPTO or a similar official overseeing the patent process.

Q: What was the central issue in Cash v. Collins regarding patent law?

The central issue was whether a method for detecting and quantifying nucleic acids using a "hybridization probe" that is not itself a nucleic acid is eligible for patent protection under 35 U.S.C. § 101.

Q: What specific technology or invention was at the heart of the Cash v. Collins dispute?

The dispute centered on a method for detecting and quantifying nucleic acids. This method utilized a "hybridization probe," which the court determined was not itself a nucleic acid, to identify natural phenomena.

Q: Which court decided the Cash v. Collins case, and what was its ruling?

The United States Court of Appeals for the Federal Circuit decided the case. The court affirmed the Patent Trial and Appeal Board's (PTAB) decision, ruling that the claimed method is ineligible for patenting.

Q: Is Cash v. Collins published?

Cash v. Collins is a published, precedential opinion. Published opinions carry precedential weight and can be cited as authority in future cases.

Q: What was the ruling in Cash v. Collins?

The court ruled in favor of the defendant in Cash v. Collins. Key holdings: The court held that the claimed method for detecting and quantifying nucleic acids using a "hybridization probe" that is not itself a "nucleic acid" is ineligible for patent protection under 35 U.S.C. § 101 because it is directed to a law of nature.; The court reasoned that the "hybridization probe" is merely a tool to detect a natural phenomenon (nucleic acid hybridization), and the claims are therefore directed to the natural phenomenon itself.; The court rejected the argument that the claims were directed to a specific application of the law of nature, finding that the claims did not add significantly more than the natural phenomenon.; The court affirmed the PTAB's decision that the claims were not patent-eligible, applying the two-step Alice/Mayo test.; The court found that the claims were not directed to a patent-eligible application of the law of nature because they did not include an inventive concept that transforms the law of nature into a patent-eligible application..

Q: Why is Cash v. Collins important?

Cash v. Collins has an impact score of 60/100, indicating significant legal impact. This decision further clarifies the application of the patent eligibility test for methods involving natural phenomena, particularly in the life sciences and diagnostic fields. It emphasizes that using a tool, even a novel one, to detect a natural law does not automatically make the method patent-eligible if the claims are fundamentally directed to the law itself.

Q: What precedent does Cash v. Collins set?

Cash v. Collins established the following key holdings: (1) The court held that the claimed method for detecting and quantifying nucleic acids using a "hybridization probe" that is not itself a "nucleic acid" is ineligible for patent protection under 35 U.S.C. § 101 because it is directed to a law of nature. (2) The court reasoned that the "hybridization probe" is merely a tool to detect a natural phenomenon (nucleic acid hybridization), and the claims are therefore directed to the natural phenomenon itself. (3) The court rejected the argument that the claims were directed to a specific application of the law of nature, finding that the claims did not add significantly more than the natural phenomenon. (4) The court affirmed the PTAB's decision that the claims were not patent-eligible, applying the two-step Alice/Mayo test. (5) The court found that the claims were not directed to a patent-eligible application of the law of nature because they did not include an inventive concept that transforms the law of nature into a patent-eligible application.

Q: What are the key holdings in Cash v. Collins?

1. The court held that the claimed method for detecting and quantifying nucleic acids using a "hybridization probe" that is not itself a "nucleic acid" is ineligible for patent protection under 35 U.S.C. § 101 because it is directed to a law of nature. 2. The court reasoned that the "hybridization probe" is merely a tool to detect a natural phenomenon (nucleic acid hybridization), and the claims are therefore directed to the natural phenomenon itself. 3. The court rejected the argument that the claims were directed to a specific application of the law of nature, finding that the claims did not add significantly more than the natural phenomenon. 4. The court affirmed the PTAB's decision that the claims were not patent-eligible, applying the two-step Alice/Mayo test. 5. The court found that the claims were not directed to a patent-eligible application of the law of nature because they did not include an inventive concept that transforms the law of nature into a patent-eligible application.

Q: What cases are related to Cash v. Collins?

Precedent cases cited or related to Cash v. Collins: Alice Corp. v. CLS Bank Int'l, 573 U.S. 208 (2014); Mayo Collaborative Servs. v. Prometheus Labs., Inc., 566 U.S. 66 (2012).

Q: What is the legal basis for the court's decision in Cash v. Collins?

The court's decision was based on 35 U.S.C. § 101, which defines patentable subject matter. Specifically, the court found that the claimed method falls within the judicially created exception for "laws of nature."

Q: How did the Federal Circuit interpret the 'laws of nature' exception in this case?

The Federal Circuit interpreted the 'laws of nature' exception to exclude methods that are directed to detecting or quantifying natural phenomena, even if they use a specific tool like a non-nucleic acid hybridization probe.

Q: What was the Patent Trial and Appeal Board's (PTAB) role in Cash v. Collins?

The PTAB had previously decided that the claimed method was not patent-eligible. The Federal Circuit affirmed this PTAB decision, agreeing with its reasoning that the claims were directed to a law of nature.

Q: Did the court consider the 'hybridization probe' to be a patentable invention in itself?

The summary focuses on the *method* claim. While the probe is a component, the court's reasoning suggests that the probe itself, when used in this context, was considered a tool for observing a natural phenomenon, and the method claims were directed to that phenomenon.

Q: What was the court's reasoning for finding the method claims directed to a natural phenomenon?

The court reasoned that the hybridization probe, even if not a nucleic acid, was merely a tool used to detect a natural phenomenon (nucleic acid sequences). The claims were therefore considered to be directed to the natural phenomenon itself, rather than a specific practical application or improvement.

Q: Does this ruling mean that all methods involving natural phenomena are unpatentable?

No, the ruling does not mean all methods involving natural phenomena are unpatentable. The key is whether the claims are *directed to* the natural phenomenon itself, as opposed to an inventive application or improvement of that phenomenon.

Q: What is the significance of the probe not being a 'nucleic acid' in the court's analysis?

The fact that the probe was not a nucleic acid was relevant to the specific claims but did not change the outcome. The court focused on the fact that the probe was used to detect a natural phenomenon, and the method claims were deemed to be directed to that phenomenon.

Q: What is 35 U.S.C. § 101, and why is it central to this case?

35 U.S.C. § 101 defines what subject matter is eligible for a patent in the United States. It is central to this case because the court had to determine if the claimed method for detecting nucleic acids fell within the categories of patentable inventions or if it was an unpatentable exception, such as a law of nature.

Q: How does Cash v. Collins affect me?

This decision further clarifies the application of the patent eligibility test for methods involving natural phenomena, particularly in the life sciences and diagnostic fields. It emphasizes that using a tool, even a novel one, to detect a natural law does not automatically make the method patent-eligible if the claims are fundamentally directed to the law itself. As a decision from a federal appellate court, its reach is national. This case is moderate in legal complexity to understand.

Q: How does this case affect companies developing diagnostic tools for genetic diseases?

Companies developing diagnostic tools that rely on detecting natural nucleic acid sequences may face challenges in obtaining patent protection for the underlying detection methods if they are deemed too closely tied to the natural phenomenon itself, rather than a specific, inventive application.

Q: What are the potential implications for biotechnology patenting after Cash v. Collins?

This decision reinforces the Federal Circuit's strict approach to patent eligibility for life sciences inventions. Companies may need to focus patent claims on specific technological improvements or applications that go beyond merely observing or detecting natural phenomena.

Q: How might this ruling impact the cost or availability of genetic testing services?

If patent protection for certain diagnostic methods becomes more difficult to obtain, it could potentially lead to increased competition and lower costs for genetic testing services, as companies may not be able to exclusively license their methods.

Q: What advice would a patent attorney give to an inventor with a similar invention after this ruling?

A patent attorney would likely advise focusing claims on the specific technological improvements, the practical application of the discovery, or the inventive steps involved in using the probe, rather than solely on the detection of the natural nucleic acid sequence itself.

Q: What is the broader impact on innovation in the field of molecular diagnostics?

The ruling could encourage innovation in the specific technological aspects of diagnostic tools and their applications, pushing inventors to develop more than just a method to observe a natural law, but rather a novel and non-obvious way to utilize it.

Q: How does Cash v. Collins relate to previous Supreme Court decisions on patent eligibility, like Alice Corp. v. CLS Bank International?

Cash v. Collins applies the framework established in cases like Alice Corp. v. CLS Bank International, which requires courts to determine if patent claims are directed to an abstract idea or law of nature, and if so, whether they contain an 'inventive concept' that transforms the claim into patent-eligible subject matter.

Q: What legal precedent existed before Cash v. Collins regarding patenting diagnostic methods?

Prior to this case, the patent eligibility of diagnostic methods, particularly those involving natural phenomena, had been a complex and evolving area of law, heavily influenced by Supreme Court decisions like Mayo Collaborative Services v. Prometheus Laboratories, Inc. and Alice Corp. v. CLS Bank International.

Q: Does this case represent a shift in patent law for biological discoveries?

This case continues a trend seen in recent Federal Circuit and Supreme Court decisions that scrutinize patent claims involving natural phenomena, particularly in the life sciences. It reinforces the need for claims to be tied to specific technological applications rather than abstract scientific principles.

Q: What was the docket number in Cash v. Collins?

The docket number for Cash v. Collins is 24-1811. This identifier is used to track the case through the court system.

Q: Can Cash v. Collins be appealed?

Potentially — decisions from federal appellate courts can be appealed to the Supreme Court of the United States via a petition for certiorari, though the Court accepts very few cases.

Q: How did the case reach the Federal Circuit?

The case reached the Federal Circuit on appeal from a decision by the Patent Trial and Appeal Board (PTAB). The PTAB had affirmed the patent examiner's rejection of the patent claims based on their ineligibility under 35 U.S.C. § 101.

Q: What was the specific procedural posture of the appeal to the Federal Circuit?

The appeal involved the Federal Circuit reviewing the PTAB's final decision regarding the patent eligibility of the claimed method. The court's task was to determine if the PTAB correctly applied the law concerning patentable subject matter under 35 U.S.C. § 101.

Q: Were there any specific evidentiary disputes or procedural rulings mentioned in the summary?

The provided summary does not detail specific evidentiary disputes or procedural rulings. It focuses on the substantive legal issue of patent eligibility and the court's interpretation of 35 U.S.C. § 101.

Q: What does it mean that the Federal Circuit 'affirmed' the PTAB's decision?

Affirming the PTAB's decision means the Federal Circuit agreed with the PTAB's conclusion that the claimed method was not eligible for patent protection. The PTAB's ruling stands as the final decision on this matter.